Jan Skoda

This study identifies trametinib and axitinib as effective inhibitors of GCTB stromal cells in vitro, showing selective activity against tumor cells compared to healthy controls.

This paper develops a cumate-inducible model to study MYC-driven neuroblastoma and identifies mitoribosomal synthetic lethality as a therapeutic target in MYC(N)-amplified tumors.

This study shows that reducing DRP1 activity in pediatric sarcomas does not improve drug sensitivity, suggesting DRP1 is not a key driver of chemoresistance in these cancers.